106 related articles for article (PubMed ID: 8308290)
1. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Rønne E; Behrendt N; Ploug M; Nielsen HJ; Wöllisch E; Weidle U; Danø K; Høyer-Hansen G
J Immunol Methods; 1994 Jan; 167(1-2):91-101. PubMed ID: 8308290
[TBL] [Abstract][Full Text] [Related]
2. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
[TBL] [Abstract][Full Text] [Related]
3. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
[TBL] [Abstract][Full Text] [Related]
4. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Magdolen V; Rettenberger P; Lopens A; Oi H; Lottspeich F; Kellermann J; Creutzburg S; Goretzki L; Weidle UH; Wilhelm O
Electrophoresis; 1995 May; 16(5):813-6. PubMed ID: 7588568
[TBL] [Abstract][Full Text] [Related]
6. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
7. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
[TBL] [Abstract][Full Text] [Related]
8. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).
Resnati M; Pallavicini I; Daverio R; Sidenius N; Bonini P; Blasi F
J Immunol Methods; 2006 Jan; 308(1-2):192-202. PubMed ID: 16386755
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
Mohanam S; Go Y; Sawaya R; Venkaiah B; Mohan PM; Kouraklis GP; Gokaslan ZL; Lagos GK; Rao JS
Int J Oncol; 1999 Jan; 14(1):169-74. PubMed ID: 9863025
[TBL] [Abstract][Full Text] [Related]
10. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Luther T; Kotzsch M; Meye A; Langerholc T; Füssel S; Olbricht N; Albrecht S; Ockert D; Muehlenweg B; Friedrich K; Grosser M; Schmitt M; Baretton G; Magdolen V
Thromb Haemost; 2003 Apr; 89(4):705-17. PubMed ID: 12669126
[TBL] [Abstract][Full Text] [Related]
12. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
13. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
14. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
15. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
16. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
18. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
19. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
20. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
